WO2015178426A1 - がん幹細胞の増殖抑制剤 - Google Patents
がん幹細胞の増殖抑制剤 Download PDFInfo
- Publication number
- WO2015178426A1 WO2015178426A1 PCT/JP2015/064523 JP2015064523W WO2015178426A1 WO 2015178426 A1 WO2015178426 A1 WO 2015178426A1 JP 2015064523 W JP2015064523 W JP 2015064523W WO 2015178426 A1 WO2015178426 A1 WO 2015178426A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer stem
- cell
- cancer
- stem cell
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 112
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 96
- 201000011510 cancer Diseases 0.000 title claims abstract description 88
- 239000003112 inhibitor Substances 0.000 title claims abstract description 25
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 22
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims abstract description 104
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 45
- 239000000556 agonist Substances 0.000 claims abstract description 35
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 20
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960002938 bexarotene Drugs 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000010261 cell growth Effects 0.000 claims description 23
- 239000003966 growth inhibitor Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000001973 epigenetic effect Effects 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000010721 Tubulin Interactions Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 118
- 229950010130 tamibarotene Drugs 0.000 abstract description 98
- 230000000694 effects Effects 0.000 abstract description 43
- 238000000034 method Methods 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 10
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 60
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 60
- 208000008443 pancreatic carcinoma Diseases 0.000 description 60
- 201000002528 pancreatic cancer Diseases 0.000 description 55
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 19
- 229960002756 azacitidine Drugs 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 16
- 229960003668 docetaxel Drugs 0.000 description 16
- 238000011580 nude mouse model Methods 0.000 description 16
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 13
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 13
- 229960000604 valproic acid Drugs 0.000 description 13
- 239000002771 cell marker Substances 0.000 description 12
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 12
- 229960005277 gemcitabine Drugs 0.000 description 12
- 229940041181 antineoplastic drug Drugs 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 206010053759 Growth retardation Diseases 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 238000004114 suspension culture Methods 0.000 description 7
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 6
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 6
- 230000005907 cancer growth Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000009422 growth inhibiting effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 101150006573 PAN1 gene Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940099419 targretin Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000002100 tumorsuppressive effect Effects 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a cancer stem cell proliferation inhibitor, and more particularly to a cancer stem cell proliferation inhibitor that exhibits resistance to existing anticancer drug treatment methods.
- Cancer treatment is an extremely fast area of progress in medicine, and its treatment methods are diverse. Nonetheless, cancer deaths are expected to continue to increase in the Ministry of Health, Labor and Welfare's demographic and World Health Organization surveys.
- One of the causes is the presence of cancer stem cells that are resistant to existing anticancer drug treatments.
- Cancer cells become highly proliferative, invasive, and metastatic due to the accumulation of genetic mutations and minute environmental changes around the cancer cells. Not all have these features. In recent years, it has been understood that only a part of the cells having these characteristics and having a high ability to develop and advance cancer are a part (Non-patent Document 1). Cancer cells with these characteristics are called cancer stem cells because they have two characteristics common to stem cells: self-renewal and multipotency that can differentiate into many types of cells. ing. So far, its presence has been confirmed in cancer types such as acute leukemia, breast cancer, colon cancer, brain tumor, prostate cancer, pancreatic cancer and the like.
- cancer stem cells are resistant to existing anticancer drug treatment methods.
- cancer stem cells remain in a microenvironment called a stem cell niche and enter a dormant period (G 0 stage) in which cell division pauses, and in this state, they are resistant to anticancer drug treatment.
- G 0 stage dormant period
- solid cancer stem cells have high expression of P-glycoprotein and the like and are resistant to anticancer agents.
- the ratio of cancer stem cells present in cancer tissue after treatment with an anticancer drug is higher than that before treatment.
- Non-patent Document 2 Non-patent Document 2
- Non-patent Document 3 the present inventors have studied for the purpose of developing a new therapeutic agent targeting cancer stem cells that can be applied clinically using cancer stem cell markers
- an object of the present invention is to provide a cancer stem cell growth inhibitor capable of effectively suppressing the growth of cancer stem cells that are resistant to existing anticancer drug treatment methods.
- cancer stem cell information transmission pathways In order to solve the above-mentioned problems, the present inventors have conducted intensive studies focusing on cancer stem cell information transmission pathways. That is, cancer stem cells are maintained in an undifferentiated state by many intracellular information transmission pathways, and the ability to maintain cancer is maintained. Substances that inhibit these signal transduction pathways are considered to be targets for novel anticancer agents by suppressing cancer growth by inducing differentiation or apoptosis of cancer stem cells. Therefore, the present inventors examined retinoids and rexinoids for their inhibitory effects on proliferation, including differentiation, apoptosis, etc. of cancer stem cells among the physiological effects such as proliferation, survival, differentiation, and apoptosis exhibited by retinoids and rexinoids. In the meantime, I thought it could be a new anticancer drug.
- cancer stem cells are part of the population of cancer cells, we will consider using cancer stem cell markers as indicators, and human pancreatic cancer cells Various cancer stem cell markers were expressed and examined using these cells.
- retinoid agonists particularly tamibarotene (Am-80) alone or in combination with rexinoid agonists, especially bexarotene, can suppress the expression of human pancreatic cancer cell numbers, morphology, and stem cell markers.
- retinoid receptor (RAR) and rexinoid receptor (RXR) are one of nuclear transcription factors, and their interaction with compounds and drugs that suppress the action of epigenetics is considered. It was found that when used in combination with anticancer drugs including molecular targets and drugs with different compounds and mechanisms of action, a dramatic growth inhibitory effect on cancer stem cells was expressed. The present invention has been completed based on such findings.
- a cancer stem cell growth inhibitor comprising a retinoid agonist as an active ingredient.
- a retinoid agonist is included in an amount of 0.5 to 20 mg per person, a retinoid agonist and a rexinoid agonist are included in a total amount of 0.5 to 500 mg per person, and an anticancer agent is included in an individual person.
- the anticancer agent is selected from the group consisting of a DNA interaction agent, an antimetabolite, a tubulin interaction agent, a molecular target therapeutic agent, an epigenetic action inhibitor, and a hormone agent (5) Or it is a cancer stem cell proliferation inhibitor of (6) description.
- cancer stem cells can be reduced by administration with a retinoid agonist alone or in combination with a rexinoid agonist. Moreover, the volume of the tumor mass can be reduced or reduced by further administering an anticancer agent. In addition, a method in which a retinoid agonist or rexinoid agonist and an anticancer agent are administered simultaneously is also useful.
- Cancers to be treated according to the present invention include acute myeloid leukemia, anti-Hodgkin lymphoma and other blood cancers that are resistant to anticancer drug treatment, pancreatic cancer, hepatocellular carcinoma, colon cancer, etc. Digestive organ cancer, lung cancer, breast cancer, prostate cancer and ovarian cancer.
- FIG. 2 is a graph showing suppression of cell proliferation activity when MIA Paca2 cells were co-treated with Am80 and 5-aza-dC for 1 week. It is a graph which shows suppression of the cell growth activity when MIA Paca2 cell is co-processed with Am80 and SAHA for 1 week. It is a graph which shows suppression of the cell growth activity when MIA Paca2 cell is co-processed with Am80 and VPA for 1 week. It is a microscope picture which shows the influence which acts on the cell migration ability of Am80 with respect to a human pancreatic cancer cell. It is a graph which shows the cancer metastasis inhibitory effect of Am80 with respect to a human pancreatic cancer cell.
- the cancer stem cell growth inhibitor of the present invention comprises a retinoid agonist as an active ingredient.
- the retinoid agonist includes pharmaceutically acceptable organic or inorganic acid addition salts thereof.
- a particularly preferred retinoid agonist is tamibarotene (Am80).
- the cancer stem cell growth inhibitor of the present invention can be preferably used in combination with a rexinoid agonist.
- the rexinoid agonist also includes a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and bexarotene (Targretin) is particularly preferable.
- the cancer stem cell growth inhibitor of the present invention has an action of enhancing the anticancer activity of an anticancer agent by using it together with various anticancer agents.
- DNA interacting agents of anticancer agents include alkylating agents cyclophosphamide, melphalan, cisplatin, carboplatin and the like, and DNA topoisomerase I inhibitor camptothecin, DNA topoisomerase II inhibitor Etoposide, daunorubicin, doxorubicin and the like.
- Preferred examples include orally administrable cyclophosphamide, melphalan, cisplatin, camptothecin, and doxorubicin.
- Antimetabolite antimetabolite agents include folate antagonists methotrexate and trimethotrexate, pyrimidine antagonists 5-fluorouracil, 5-aza-dC, azacitidine, cytarabine and gemcitabine, and purine antagonist fludarabine.
- Preferred examples include orally administrable methotrexate, 5-fluorouracil, 5-aza-dC, azacitidine, cytarabine, gemcitabine, and fludarabine.
- paclitaxel and docetaxel are preferable.
- molecular targeted therapeutic agents for anticancer agents include cyclooxygenase 2 inhibitors celecoxib and rofecoxib, growth factor signal inhibitors erlotinib and imanitiv.
- cyclooxygenase 2 inhibitors celecoxib and rofecoxib include cyclooxygenase 2 inhibitors celecoxib and rofecoxib, growth factor signal inhibitors erlotinib and imanitiv.
- orally administrable gefitinib and imanitib are mentioned.
- epigenetic action inhibitors of anticancer agents include azacitidine as a DNA methylation inhibitor, valproic acid as a histone deacetylase inhibitor, SAHA (Vorinostat), and Romidepsin (FK228).
- Preferred examples include orally administrable azacitidine, valproic acid, and SAHA (Vorinostat).
- hormonal agents as anticancer agents include leuprolide acetate, goserelin acetate, antiestrogenic agent tamoxifen, antiandrogenic agent flutamide, bicalutamide, enzalutamide and the like.
- tamoxifen, flutamide, bicalutamide, and enzalutamide that can be administered orally are used.
- combination of anticancer agents examples include a combination of paclitaxel (or docetaxel), cisplatin and TS-1, a combination of docetaxel and oxaliplatin, a combination of docetaxel and a molecular target drug, etc. It is not limited.
- the cancer stem cell growth inhibitor of the present invention is administered by any of oral, rectal, topical, or parenteral, intravenous or intratumoral injection, so that cancer stem cells in humans and It can effectively inhibit the growth of cancer mass.
- the cancer stem cell growth inhibitor of the present invention may be a solid, gel, or liquid such as a tablet, capsule, pill, or liposome (see Cancer Chemotherapy Handbook version 2, 15-34 (1994)).
- the retinoid agonist and the rexinoid agonist may be included in a total amount of 0.5 to 500 mg per person, and the anticancer agent may be included in an amount of 1.0 to 1000 mg per person. Further, the retinoid agonist can be preferably 0.5 to 20 mg per human individual.
- the cancer stem cell growth inhibitor of the present invention is preferably a retinoid agonist alone or in combination with a rexinoid agonist, simultaneously administered with an anticancer agent to differentiate cancer stem cells and induce cancer cells by causing apoptosis. Inhibit or reduce growth. In order to suppress the growth of cancer stem cells, it can be administered for 2 weeks to 2 years as necessary.
- Example 1 ⁇ Proliferation inhibitory effect of Am80 on human pancreatic cancer cell spheroids>
- a human pancreatic cancer cell line is used and cultured in a medium with DMEM / F12 supplemented with B27, 20 ng / mL EGF, 20 ng / mL bFGF, and 4 ⁇ g / mL heparin using a low adhesion dish, a cell mass is formed, It can be cultured in a floating state, and can be cultured in a state in which some cancer stem cell markers and other markers reported in other cancers are increased.
- a cell mass containing this cancer stem cell marker positive cell was cultured in a medium supplemented with Am80 for 1 week, and the influence on the proliferation of the cell mass and the expression level of the cancer stem cell marker was analyzed.
- the proliferation of the cell mass was suppressed depending on the concentration of tamibarotene (Am80).
- the number of cell clusters decreased, and the number of cells also decreased in a concentration-dependent manner (FIG. 1).
- this cell mass was cultured in a medium containing Am80 for a total of 2 weeks, the cell mass became even smaller and the number of cells decreased. From the above, it has been clarified that Am80 has an action of suppressing the proliferation of a cell population containing pancreatic cancer stem cells.
- Example 2 ⁇ Inhibitory effect of Am80 on ALDH activity of human pancreatic cancer cell Panc-1 spheroid> As shown in Example 1, Am80 suppresses the formation of a cell mass in a suspension culture state of a pancreatic cancer cell line, and thus it is considered that cancer stem cells that are the seeds may be reduced. It is known that hematopoietic stem cells and progenitor cells have high aldehyde dehydrogenase (ALDH) activity and low activity in differentiated cells.
- ADH aldehyde dehydrogenase
- Bodipy-aminoacetate-positive cells produced by addition of the precursor Bodipy-aminoacetaldehyde (ALDEFLUOR, Stem Cell Technologies) to the pancreatic cancer cells added with Am80 for 1 week in suspension culture and metabolized by aldehyde dehydrogenase activity.
- ADEFLUOR Bodipy-aminoacetaldehyde
- Am80 was added and cultured, ALDH activity decreased in a concentration-dependent manner and the amount of cancer stem cells decreased (FIG. 2).
- Example 3 ⁇ Inhibitory effect of Am80 on CD24 + / CD44 + / ESA + cells present in human pancreatic cancer cell Panc-1 spheroid> Pancreatic cancer cells added with Am80 and suspended in culture for 1 week were analyzed by flow cytometry using a primary antibody fluorescently labeled for the expression of various cancer stem cell surface markers at the protein level.
- CD24 + / CD44 + It was confirmed that the presence rate of / ESA + positive cells was significantly decreased by the addition of Am80.
- the presence of CD24 + / CD44 + / ESA + positive cells was halved in the presence of 10 ⁇ M Am80. That is, it was suggested that Am80 may reduce cancer stem cells (FIG. 3).
- Example 4 ⁇ Differentiation marker enhancement effect on human pancreatic cancer cell spheroids>
- total RNA was extracted from pancreatic cancer cells that had been cultured in suspension for 1 week after adding Am80, and quantitative RT-PCR was performed using primers for a pancreatic tissue-specific differentiation marker.
- genes such as Pdx1 and glucagon were detected. It was observed that the expression increased depending on the concentration of Am80. This suggested that Am80 may promote differentiation of a cell population containing cancer stem cells (FIG. 4).
- Example 5 ⁇ Effects of combined use of Am80 and bexarotene on human pancreatic cancer cell MIA-Paca2 spheroid on cell proliferation activity> MIA-Paca2 cell cluster containing cancer stem cell marker-positive cells is suspended in Am80 (10 nM-1 ⁇ M) and Bexarotene-added medium for 1 week, then MTT reagent (Cell Counting Kit-8, Dojindo) is added and further cultured for 3 hours After that, the influence of the cell mass on the cell proliferation activity was analyzed by measuring the absorbance at 450 nm (OD450). As a result, the cell proliferation activity of the cell mass was gently suppressed depending on the concentration of Am80 and bexarotene (FIG. 5).
- Example 6 ⁇ Effects of combined use of Am80 and DNA methyl inhibitor 5-aza-dC on human pancreatic cancer cell MIA-Paca2 spheroid on proliferation activity> MIA-Paca2 cell mass containing cancer stem cell marker positive cells was suspended in Am80 (10 nM-1 ⁇ M) and 5-aza-dC-added medium for 1 week, and then MTT reagent (Cell Counting Kit-8, Dojindo) was added. After further culturing for 3 hours, the influence of the cell mass on cell proliferation was analyzed by measuring the absorbance at 450 nm. As a result, the cell proliferation activity of the cell mass was suppressed depending on the concentration of Am80 and 5-aza-dC (FIG. 6).
- Example 7 ⁇ Effects of combined use of Am80 and histone deacetylase inhibitor / SAHA on human pancreatic cancer cell MIA-Paca2 spheroids on growth suppression> MIA-Paca2 cell mass containing cancer stem cell marker-positive cells is suspended in Am80 (10 nM-1 ⁇ M) and SAHA for 1 week in suspension culture, then MTT reagent (Cell Counting Kit-8, Dojindo) is added and further cultured for 3 hours After that, the influence of the cell mass on the cell proliferation activity was analyzed by measuring the absorbance at 450 nm. As a result, the cell proliferation activity of the cell mass was gently suppressed depending on the concentration of Am80 and SAHA (FIG. 7).
- Example 8 ⁇ Effects of combined use of Am80 and histone deacetylase inhibitor valproic acid (VPA) on human pancreatic cancer cell MIA-Paca2 spheroid on growth suppression> MIA-Paca2 cell mass containing cancer stem cell marker positive cells is suspended in Am80 (6.3 nM to 100 nM) and VPA-added medium for 1 week, then MTT reagent (Cell Counting Kit-8, Dojindo) is added, and further 3 After incubation for a period of time, the effect of cell mass on cell proliferation was measured by absorbance at 450 nm. As a result, Am80 and VPA showed synergistic cell growth inhibitory activity of the cell mass (FIG. 8).
- Example 9 ⁇ Effect of Am80 on cell migration ability of human pancreatic cancer stem cells> After pancreatic cancer cells including pancreatic cancer stem cells were separated into CD133 positive cells and negative cells with magnetic antibody beads, 1 ⁇ M Am80 was added and cultured in a Boyden chamber, and cells that migrated behind the membrane were observed. As a result, Am80 significantly suppressed the cell migration ability in the cancer stem cell fraction of CD133 positive cells (FIG. 9).
- Example 10 ⁇ Am80's cancer metastasis inhibiting effect on human pancreatic cancer cells> Pancreatic cancer cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted into the pancreas of nude mice, and the tumor size (Tumor volume) formed after 1 month of metastasis to the liver was measured. Am80 was administered at 3 mg / kg ⁇ day for 1 month. As a result, pancreatic cancer metastasis could be suppressed as compared with the control (FIG. 10).
- Example 11 ⁇ Tumor suppressive effect of Am80 on human pancreatic cancer cells> Pancreas cancer stem cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted subcutaneously into nude mice, and after 2 weeks, Am80 was given at 3 mg / kg ⁇ day to mice in which tumor formation was confirmed. Administered for 1 month (Days after Am80 treatment). As a result, although the influence on body weight (Body weight) was not observed (A), the growth of pancreatic cancer was able to be suppressed in the body as compared with the control (B) (FIG. 11).
- Example 12 ⁇ Inhibitory effect of Am80 on human pancreatic cancer stem cells transplanted into nude mice> Pancreas cancer stem cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted subcutaneously into nude mice, and after 2 weeks, Am80 was given at 3 mg / kg ⁇ day to mice in which tumor formation was confirmed. Administered for 1 month. Thereafter, the tumor was removed, treated with trypsin, and the ratio of pancreatic cancer stem cells was measured by flow cytometry using an anti-CD133 antibody. As a result, Am80 has an action of suppressing pancreatic cancer stem cells in the body as compared with the control. (Fig. 12).
- Example 13 ⁇ Tumor suppressive effect of Am80 on human pancreatic cancer cells> Pancreas cancer stem cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted subcutaneously into nude mice, and after 2 weeks, Am80 was given at 3 mg / kg ⁇ day to mice in which tumor formation was confirmed. Administered for 1 month. As a result of preparing pathological specimens of each tumor and evaluating the cell tissue morphology, it was found that the pancreatic cancer tissue morphology was differentiated compared to the control group to which Am80 was not administered (FIG. 13). ).
- Example 14 Combination effect of anticancer agent gemcitabine and Am80 on human pancreatic cancer cells> Human pancreatic cancer cells were cultured in suspension culture for 1 week after adding gemcitabine (10 nM), then Am80 was further added and suspended in suspension for 1 week, and the number of cell masses (Number of colonies formed) was counted. As a result, it was found that Am80 also has a sphere formation inhibitory effect in vitro against pancreatic cancer cells after treatment with an anticancer agent (FIG. 14).
- Example 15 Combination effect of anticancer agent gemcitabine and Am80 on human pancreatic cancer cells>
- Pancreas cancer stem cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted subcutaneously into nude mice, and after 2 weeks, Am80 was given at 3 mg / kg ⁇ day to mice in which tumor formation was confirmed.
- Daily administration, gemcitabine was administered at 50 mg / kg every 3 days for 1 month (Days after Am80 and Gem treatment).
- simultaneous administration of Am80 and gemcitabine more strongly suppressed the growth of pancreatic cancer in the body than control (non-administration of Am80 and gemcitabine) and gemcitabine alone (FIG. 15).
- Gem represents gemcitabine.
- Example 16 Combination effect of epigenetic inhibitor VPA and Am80 on human pancreatic cancer cells>
- Pancreas cancer stem cells (1 ⁇ 10 6 cells) containing pancreatic cancer stem cells were transplanted subcutaneously into nude mice, and after 2 weeks, Am80 was given at 3 mg / kg ⁇ day to mice in which tumor formation was confirmed.
- VPA was administered daily at 500 mg / kg every 3 days for 1 month (Days after Am80 and VPA treatment).
- it was found that coadministration of Am80 and VPA more strongly suppressed the growth of pancreatic cancer in the body as compared with control (no Am80 and VPA administration), VPA alone administration, and Am80 alone administration (FIG. 16). ).
- Example 17 ⁇ Effects of combined use of Am80 and Docetaxel (DXL) on human pancreatic cancer cell MIA-Paca2 / nude mice on growth suppression>
- a 6-week-old female BALB / cAJcl-nu nude mouse (4 mice / group, 5 mice only in the control group) was subcutaneously injected with a tumor fragment of human pancreatic cancer cell MIA-Paca2 containing cancer stem cell marker-positive cells. Implanted using a trocar needle. Administration was started when the tumor volume reached 100-200 mm 3 .
- Am80 was orally administered at a dose of 2 mg / kg once a day for 21 days, and DXL was intravenously administered at a dose of 5 mg / kg three times at intervals of 4 days from the first day.
- the combination group was administered by the same dosage and administration method as each single agent, and the tumor diameter was measured until the day after the end of administration (day 22). From the measured values of the major axis and the minor axis of the tumor and the tumor volume was determined (mm 3) from the major axis ⁇ minor axis 2/2 equation.
- physiological saline was intraperitoneally administered three times at 4-day intervals from the first day.
- Example 18 ⁇ Effects of combined use of Am80 and DNA methylation inhibitor azacitidine (5-AZ) on human leukemia cell line Kasumi-1>
- a human leukemia cell line Kasumi-1 containing cancer stem cell marker-positive cells was cultured in RPMI 1640 medium supplemented with 20% FBS, and the growth inhibitory effect of combination of Am80 and 5-AZ was examined using Isobrogram.
- Each IC50 value was 1.0 ⁇ M and 8.4 ⁇ M.
- an additive effect is shown on the straight line connecting 1.0 of both axes, and a synergistic effect is shown on the lower side of the straight line.
- the combination of Am80 and 5-AZ showed a synergistic effect on the growth inhibitory action (FIG. 17).
- Example 19 ⁇ Effects of combined use of Am80 and DNA methylation inhibitor 5-AZ on human breast cancer cell line MCF-7 on growth suppression>
- a human breast cancer cell line MCF-7 containing cancer stem cell marker-positive cells was cultured in RPMI 1640 medium supplemented with 2% FBS, and the growth inhibitory effect of combination use of Am80 and 5-AZ was examined. Since the IC50 values after exposure for 96 hours were 1 ⁇ M and 20 ⁇ M, Am80 was in a concentration range of 0.125 ⁇ M to 1 ⁇ M with a common ratio of 2, and 5-AZ was 2.5 ⁇ M to 20 ⁇ M with a common ratio of 2. The growth inhibitory effect in the concentration range was examined. In the case of combined use, the growth inhibitory action was examined using these concentrations. The combination of Am80 and 5-AZ showed a synergistic effect on the growth inhibitory action (FIG. 18).
- Example 20 ⁇ Effects of combined use of Am80 and Docetaxel (DXL) on human breast cancer cell line MCF-7 / nude mice on growth inhibition>
- a 6-week-old female BALB / cAJcl-nu nude mouse (5 / group) was transplanted with a tumor fragment of human breast cancer cell line MCF-7 containing cancer stem cell marker positive cells subcutaneously on the dorsal region using a trocar needle. .
- Administration was started when the tumor volume reached 100-200 mm 3 .
- Am80 was orally administered at a dose of 1 mg / kg once / day for 21 consecutive days, and DXL was intravenously administered at a dose of 3.5 mg / kg three times at intervals of 4 days from the first day.
- the combination group was administered by the same dosage and administration method as each single agent, and the tumor diameter was measured until the day after the end of administration (day 22).
- the major axis and the minor axis of the tumors were measured using calipers, and the tumor volume was determined (mm 3) from the major axis ⁇ minor axis 2/2 equation.
- physiological saline was intraperitoneally administered three times at 4-day intervals from the first day.
- Example 21 ⁇ Effects of combined use of Am80 and DNA methylation inhibitor 5-AZ on human prostate cancer cell line LNCaP on growth suppression>
- a human prostate cancer cell line LNCaP containing cancer stem cell marker positive cells was cultured in RPMI1640 medium supplemented with 10% FBS, and the growth inhibitory effect of combination use of Am80 and 5-AZ was examined. Since the IC50 values after exposure for 96 hours were 2 ⁇ M and 25 ⁇ M, Am80 was in a concentration range of 0.125 ⁇ M to 1 ⁇ M with a common ratio of 2, and 5-AZ was 1.56 ⁇ M to 12.2. The growth inhibitory effect in the concentration range of 5 ⁇ M was examined. In the case of combined use, the growth inhibitory action was examined using these concentrations. The combination of Am80 and 5-AZ showed a synergistic effect on the growth inhibitory action (FIG. 19).
- Example 22 ⁇ Effects of combined use of Am80 and Docetaxel (DXL) on human prostate cancer cell line LNCaP / nude mice on growth suppression>
- a 6-week-old female BALB / cAJcl-nu nude mouse (4 mice / group) was transplanted with a tumor piece of a human prostate cancer cell line LNCaP containing a cancer stem cell marker positive cell subcutaneously on the dorsal region using a trocar needle. .
- Administration was started when the tumor volume reached 100-200 mm 3 .
- Am80 was orally administered at a dose of 1 mg / kg once / day for 21 consecutive days, and DXL was intravenously administered at a dose of 5 mg / kg three times at intervals of 4 days from the first day.
- the combination group was administered by the same dosage and administration method as each single agent, and the tumor diameter was measured until the day after the end of administration (day 22).
- the major axis and the minor axis of the tumors were measured using calipers, and the tumor volume was determined (mm 3) from the major axis ⁇ minor axis 2/2 equation.
- physiological saline was intraperitoneally administered three times at 4-day intervals from the first day.
- Retinoid agonist tamibarotene (Am-80) alone or combined with rexinoid agonist bexarotene (Targretin) suppresses marker expression and proliferation of human pancreatic cancer stem cells, and is used in combination with various anticancer agents As a result, it was confirmed that the effect of the anticancer agent was enhanced. Furthermore, it was confirmed that the effect of anticancer agents was enhanced by using Am80 and various anticancer agents in combination for various cancers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
即ち、がん幹細胞は、多くの細胞内情報伝達経路によって未分化状態が維持され、がんを維持する能力が保たれている。これらの情報伝達経路を阻害する物質はがん幹細胞の分化またはアポトーシスを誘導することによってがんの増殖を抑制することにより新規抗がん剤の標的になると考えられる。
そこで本発明者らは、レチノイドおよびレキシノイドを用いて、レチノイドおよびレキシノイドが発揮する増殖、生存、分化、アポトーシス等の生理学的作用の内、がん幹細胞に対する分化、アポトーシス等を含む増殖抑制作用を検討する中で、新規抗がん剤になりうると考えた。
(1)レチノイドアゴニストを有効成分とするがん幹細胞の増殖抑制剤である。
本発明のがん幹細胞の増殖抑制剤はレチノイドアゴニストを有効成分とするものである。本発明において、レチノイドアゴニストにはその薬剤学的に許容可能な有機又は無機の酸付加塩を含む。特に、好ましいレチノイドアゴニストとしてはタミバロテン(Am80)を挙げることができる。
本発明において、抗がん剤のDNA相互作用剤としては、アルキル化剤のシクロホスファミド、メルファラン、シスプラチン、カルボプラチン等が挙げられ、またDNAトポイソメラーゼI阻害剤のカンプトテシン、DNAトポイソメラーゼII阻害剤のエトポシド、ダウノルビシン、ドキソルビシン等が挙げられる。好ましくは、経口投与可能なシクロホスファミド、メルファラン、シスプラチン、カンプトテシン、ドキソルビシンが挙げられる。
<ヒトすい臓がん細胞スフェロイドに対するAm80の増殖抑制効果>
ヒトすい臓がん細胞株を用いてDMEM/F12にB27、20ng/mL EGF、20ng/mL bFGF、及び4μg/mL heparinを添加した培地で低接着ディッシュを用いて培養すると、細胞塊を形成し、浮遊状態で培養することが可能であり、いくつかのがん幹細胞マーカーと他のがんで報告されているマーカーが増加した状態で培養できる。まず、このがん幹細胞マーカー陽性細胞を含む細胞塊をAm80添加培地で1週間培養し、細胞塊の増殖やがん幹細胞マーカーの発現量への影響を解析した。その結果、タミバロテン(Am80)の濃度依存的に細胞塊の増殖は抑制された。細胞塊の数が減少し、細胞数も濃度依存的に減少した(図1)。さらにこの細胞塊をAm80含有培地で合計2週間培養すると、よりいっそう細胞塊は小さくなり、細胞数が減少した。以上のことからAm80はすい臓がん幹細胞を含む細胞集団の増殖を抑制する作用をもつことが明らかとなった。
<ヒトすい臓がん細胞Panc-1スフェロイドのALDH活性に対するAm80の抑制効果>
実施例1に示すようにAm80は、すい臓がん細胞株の浮遊培養状態での細胞塊形成を抑制することから、その種となるがん幹細胞が減少している可能性が考えられた。造血幹細胞や前駆細胞などでは、アルデヒドデヒドロゲナーゼ(ALDH)活性が高く、分化細胞では活性が低いことが知られている。そこでAm80を添加して1週間浮遊培養したすい臓がん細胞に、前駆体Bodipy-aminoacetaldehyde(ALDEFLUOR, Stem Cell Technologies)を加え、アルデヒドデヒドロゲナーゼ活性で代謝されて生成されるBodipy-aminoacetateの蛍光陽性細胞数をフローサイトメトリーで定量解析した。その結果、Am80を添加して培養すると、濃度依存的にALDH活性が低下し、がん幹細胞量が減少する可能性が示された(図2)。
<ヒトすい臓がん細胞Panc-1スフェロイドに存在するCD24+/CD44+/ESA+細胞に対するAm80の抑制効果>
Am80を添加して1週間浮遊培養したすい臓がん細胞を、タンパク質レベルで各種がん幹細胞表面マーカーの発現を蛍光標識した1次抗体を用いてフローサイトメトリーで解析したところ、特に、CD24+/CD44+/ESA+陽性細胞の存在率がAm80添加により有意に発現減少することが確認された。特に10μMのAm80存在下ではCD24+/CD44+/ESA+陽性細胞の存在率が半減した。すなわちAm80はがん幹細胞を減少させる可能性が示唆された(図3)。
<ヒトすい臓がん細胞スフェロイドに対する分化マーカー増強効果>
次に、Am80を添加して1週間浮遊培養したすい臓がん細胞からtotal RNAを抽出し、すい臓組織特異的な分化マーカーに対するプライマーで定量的RT-PCRを行ったところ、Pdx1やグルカゴンなどの遺伝子発現がAm80の濃度依存的に上昇する様子が観察された。このことからAm80ががん幹細胞を含む細胞集団の分化を促進している可能性が示唆された(図4)。
<ヒトすい臓がん細胞MIA-Paca2スフェロイドに対するAm80とベキサロテン(bexarotene)との併用における細胞増殖活性への影響>
がん幹細胞マーカー陽性細胞を含むMIA-Paca2細胞塊をAm80(10nM-1μM)とベキサロテン添加培地で1週間浮遊培養後、MTT試薬(Cell Counting Kit-8, Dojindo)を添加してさらに3時間培養した後に、細胞塊の細胞増殖活性への影響を450nmの吸光度(OD450)を測定して解析した。その結果、Am80とベキサロテンの濃度依存的にゆるやかに細胞塊の細胞増殖活性が抑制された(図5)。
<ヒトすい臓がん細胞MIA-Paca2スフェロイドに対するAm80とDNAメチル阻害剤・5-aza-dCとの併用における増殖活性への影響>
がん幹細胞マーカー陽性細胞を含むMIA-Paca2細胞塊をAm80(10nM-1μM)と5-aza-dC添加培地で1週間浮遊培養後、MTT試薬(Cell Counting Kit-8, Dojindo)を添加してさらに3時間培養した後に、細胞塊の細胞増殖への影響を450nmの吸光度を測定して解析した。その結果、Am80と5-aza-dCの濃度依存的に細胞塊の細胞増殖活性が抑制された(図6)。
<ヒトすい臓がん細胞MIA-Paca2スフェロイドに対するAm80とヒストンデアセチラーゼ阻害剤・SAHAとの併用における増殖抑制への影響>
がん幹細胞マーカー陽性細胞を含むMIA-Paca2細胞塊をAm80(10nM-1μM)とSAHA添加培地で1週間浮遊培養後、MTT試薬(Cell Counting Kit-8, Dojindo)を添加してさらに3時間培養した後に、細胞塊の細胞増殖活性への影響を450nmの吸光度を測定して解析した。その結果、Am80とSAHAの濃度依存的に細胞塊の細胞増殖活性がゆるやかに抑制された(図7)。
<ヒトすい臓がん細胞MIA-Paca2スフェロイドに対するAm80とヒストンデアセチラーゼ阻害剤・バルプロ酸(VPA)との併用における増殖抑制への影響>
がん幹細胞マーカー陽性細胞を含むMIA-Paca2細胞塊をAm80(6.3nM~100nM)とVPA添加培地で1週間浮遊培養後、MTT試薬(Cell Counting Kit-8, Dojindo)を添加してさらに3時間培養した後に、細胞塊の細胞増殖への影響を450nmの吸光度で測定した。その結果、Am80とVPAは、相乗的な細胞塊の細胞増殖阻害活性を示した(図8)。
<ヒトすい臓がん幹細胞に対するAm80の細胞遊走能への影響>
膵臓がん幹細胞を含むすい臓がん細胞を磁気抗体ビーズでCD133陽性細胞と陰性細胞とに分離後、1μMのAm80を添加しボイデンチャンバーで培養し、膜裏側に遊走する細胞を観察した。その結果、Am80はCD133陽性細胞のがん幹細胞画分において顕著に細胞遊走能を抑制した(図9)。
<ヒトすい臓がん細胞に対するAm80のがん転移抑制効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの膵臓に移植し、1か月後肝臓へ転移し形成した腫瘍の大きさ(Tumor volume)を測定した。Am80は3mg/kg・dayで1か月間投与した。その結果、コントロールと比較してすい臓がんの転移を抑制することができた(図10)。
<ヒトすい臓がん細胞に対するAm80の造腫瘍抑制効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの皮下に移植し、2週間後、腫瘍を形成が確認されたマウスに対して、Am80を3mg/kg・dayで1か月間投与した(Days after Am80 treatment)。その結果、体重(Body weight)に対する影響は見られないが(A)、コントロールと比較してすい臓がんの増殖を体内で抑制することができた(B)(図11)。
<ヌードマウスに移植したヒトすい臓がん幹細胞に対するAm80の抑制効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの皮下に移植し、2週間後、腫瘍を形成が確認されたマウスに対して、Am80を3mg/kg・dayで1か月間投与した。その後、腫瘍を取出し、トリプシン処理し、抗CD133抗体を用いてすい臓がん幹細胞の割合をフローサイトメトリーで測定した結果、Am80はコントロールと比較してすい臓がん幹細胞を体内で抑制する作用を持っていることが分かった(図12)。
<ヒトすい臓がん細胞に対するAm80の造腫瘍抑制効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの皮下に移植し、2週間後、腫瘍を形成が確認されたマウスに対して、Am80を3mg/kg・dayで1か月間投与した。それぞれの腫瘍の病理標本を作製し、細胞組織形態を評価してみた結果、Am80を投与しなかったコントロール群と比較してすい臓がん組織の形態が分化型を示すことが分かった(図13)。
<ヒトすい臓がん細胞に対する抗がん剤・ジェムシタビンとAm80の併用効果>
ヒトすい臓がん細胞を浮遊培養状態でジェムシタビン(10nM)を加えて1週間培養した後、さらにAm80を添加して1週間浮遊培養し、細胞塊の数(Number of colonies formed)をカウントした。その結果、Am80が抗がん剤処理後のすい臓がん細胞に対してもin vitroでスフェア形成抑制効果を持つことが分かった(図14)。
<ヒトすい臓がん細胞に対する抗がん剤・ジェムシタビンとAm80の併用効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの皮下に移植し、2週間後、腫瘍を形成が確認されたマウスに対して、Am80を3mg/kg・dayで毎日投与し、ジェムシタビンを50mg/kgで3日おきに1か月間投与した(Days after Am80 and Gem treatment)。その結果、コントロール(Am80およびジェムシタビン非投与)やジェムシタビン単独投与と比較して、Am80とジェムシタビンの同時投与はすい臓がんの増殖を体内でより強く抑制することが分かった(図15)。ここで、Gemはジェムシタビンを表す。
<ヒトすい臓がん細胞に対するエピジェネティック阻害剤VPAとAm80の併用効果>
膵臓がん幹細胞を含むすい臓がん細胞(1×106個)をヌードマウスの皮下に移植し、2週間後、腫瘍を形成が確認されたマウスに対して、Am80を3mg/kg・dayで毎日投与し、VPAを500mg/kgで3日おきに1か月間投与した(Days after Am80 and VPA treatment)。その結果、コントロール(Am80およびVPA非投与)やVPA単独投与、Am80単独投与と比較して、Am80とVPAの同時投与はすい臓がんの増殖を体内でより強く抑制することが分かった(図16)。
〔実施例17〕
<ヒトすい臓がん細胞MIA-Paca2/ヌードマウスに対するAm80とDocetaxel(DXL)との併用における増殖抑制への影響>
6週齢の雌性BALB/cAJcl-nuヌードマウス(4匹/群、対照群のみ5匹)にがん幹細胞マーカー陽性細胞を含むヒトすい臓がん細胞MIA-Paca2の腫瘍片を背側部皮下にトロカー針を用いて移植した。腫瘍体積が100-200mm3に達した時点から投与を開始した。Am80は2mg/kgを1回/日、連日21日間経口投与し、DXLは、5mg/kgを1日目より4日間隔で3回、静脈内投与した。併用群は各単剤と同じ用量、投与法で投与し、投与終了翌日(22日目)まで腫瘍径を測定した。腫瘍の長径及び短径の測定値から長径×短径2/2の式から腫瘍体積(mm3)を求めた。なお、対照群には生理食塩液を1日目より4日間隔で3回、腹腔内投与した。その結果、Am80とDXLとの併用は各単剤の効果を上回る相乗的な細胞増殖阻害活性を示した。結果を下記表1に示す。
<ヒト白血病細胞株Kasumi-1に対するAm80とDNAメチル化阻害剤・アザシチジン(5-AZ)との併用における増殖抑制への影響>
がん幹細胞マーカー陽性細胞を含むヒト白血病細胞株Kasumi-1を20%FBS添加したRPMI1640培地にて培養し、Isobrogramを用いてAm80と5-AZとの併用による増殖抑制作用を検討した。それぞれのIC50値は1.0μM、8.4μMであった。これらの濃度を1.0とした時の併用効果の比率を求めて両軸の1.0を結んだ直線上の場合は相加効果を示し、直線より下側の場合には相乗効果を示す。Am80と5-AZの併用は、増殖抑制作用において相乗効果を示した(図17)。
<ヒト乳がん細胞株MCF-7に対するAm80とDNAメチル化阻害剤・5-AZとの併用における増殖抑制への影響>
がん幹細胞マーカー陽性細胞を含むヒト乳がん細胞株MCF-7を2%FBS添加したRPMI1640培地にて培養し、Am80と5-AZとの併用による増殖抑制作用を検討した。96時間の暴露によるそれぞれのIC50値は1μM、20μMであったので、Am80は公比2で0.125μMから1μMの濃度範囲で、また、5-AZは公比2で2.5μMから20μMの濃度範囲での増殖抑制作用を検討した。併用の場合には、これらの濃度を用いて増殖抑制作用を検討した。Am80と5-AZの併用は、増殖抑制作用において相乗効果を示した(図18)。
<ヒト乳がん細胞株MCF-7/ヌードマウスに対するAm80とDocetaxel(DXL)との併用における増殖抑制への影響>
6週齢の雌性BALB/cAJcl-nuヌードマウス(5匹/群)にがん幹細胞マーカー陽性細胞を含むヒト乳がん細胞株MCF-7の腫瘍片を背側部皮下にトロカー針を用いて移植した。腫瘍体積が100-200mm3に達した時点から投与を開始した。Am80は1mg/kgを1回/日、連日21日間経口投与し、DXLは、3.5mg/kgを1日目より4日間隔で3回、静脈内投与した。併用群は各単剤と同じ用量、投与法で投与し、投与終了翌日(22日目)まで腫瘍径を測定した。腫瘍の長径及び短径を、キャリパーを用いて測定し、長径×短径2/2の式から腫瘍体積(mm3)を求めた。なお、対照群には生理食塩液を1日目より4日間隔で3回、腹腔内投与した。その結果、増殖の遅いヒト乳がん細胞株MCF-7に対して、Am80とDXLとの併用は各単剤の効果を上回る相乗的な細胞増殖阻害活性を示した。結果を下記表2に示す。
<ヒト前立腺がん細胞株LNCaPに対するAm80とDNAメチル化阻害剤・5-AZとの併用における増殖抑制への影響>
がん幹細胞マーカー陽性細胞を含むヒト前立腺がん細胞株LNCaPを10%FBS添加したRPMI1640培地にて培養し、Am80と5-AZとの併用による増殖抑制作用を検討した。96時間の暴露によるそれぞれのIC50値は2μM、25μMであったので、Am80は公比2で0.125μMから1μMの濃度範囲で、また、5-AZは公比2で1.56μMから12.5μMの濃度範囲での増殖抑制作用を検討した。併用の場合には、これらの濃度を用いて増殖抑制作用を検討した。Am80と5-AZの併用は、増殖抑制作用において相乗効果を示した(図19)。
<ヒト前立腺がん細胞株LNCaP/ヌードマウスに対するAm80とDocetaxel(DXL)との併用における増殖抑制への影響>
6週齢の雌性BALB/cAJcl-nuヌードマウス(4匹/群)にがん幹細胞マーカー陽性細胞を含むヒト前立腺がん細胞株LNCaPの腫瘍片を背側部皮下にトロカー針を用いて移植した。腫瘍体積が100-200mm3に達した時点から投与を開始した。Am80は1mg/kgを1回/日、連日21日間経口投与し、DXLは、5mg/kgを1日目より4日間隔で3回、静脈内投与した。併用群は各単剤と同じ用量、投与法で投与し、投与終了翌日(22日目)まで腫瘍径を測定した。腫瘍の長径及び短径を、キャリパーを用いて測定し、長径×短径2/2の式から腫瘍体積(mm3)を求めた。なお、対照群には生理食塩液を1日目より4日間隔で3回、腹腔内投与した。その結果、ヒト前立腺がん細胞株LNCaPに対して、Am80とDXLとの併用は各単剤の効果を上回る相乗的な細胞増殖阻害活性を示した。結果を下記表3に示す。
Claims (7)
- レチノイドアゴニストを有効成分とするがん幹細胞の増殖抑制剤。
- 前記レチノイドアゴニストがタミバロテン(Am-80)である請求項1記載のがん幹細胞の増殖抑制剤。
- 更に、レキシノイドアゴニストを有効成分とする請求項1または2記載のがん幹細胞の増殖抑制剤。
- 前記レキシノイドアゴニストがベキサロテンである請求項3記載のがん幹細胞の増殖抑制剤。
- 抗がん剤を含む請求項1~4のうちいずれか一項記載のがん幹細胞の増殖抑制剤。
- レチノイドアゴニストをヒト一個体あたり0.5~20mgを含み、レチノイドアゴニストとレキシノイドアゴニストとを合計でヒト一個体あたり0.5~500mgを含み、かつ、抗がん剤をヒト一個体あたり1.0~1000mgを含む請求項5記載のがん幹細胞の増殖抑制剤。
- 前記抗がん剤が、DNA相互作用剤、代謝拮抗剤、チューブリン相互作用剤、分子標的治療剤、エピジェネティックスの作用阻害剤およびホルモン剤からなる群から選ばれる請求項5または6記載のがん幹細胞の増殖抑制剤。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/312,484 US20170079942A1 (en) | 2014-05-21 | 2015-05-20 | Cancer stem cell proliferation inhibitor |
KR1020167034364A KR20170005069A (ko) | 2014-05-21 | 2015-05-20 | 암 줄기 세포의 증식 억제제 |
CA2949640A CA2949640A1 (en) | 2014-05-21 | 2015-05-20 | Cancer stem cell proliferation inhibitor |
RU2016150116A RU2016150116A (ru) | 2014-05-21 | 2015-05-20 | Ингибитор пролиферации раковых стволовых клеток |
CN201580025982.2A CN106456770A (zh) | 2014-05-21 | 2015-05-20 | 癌干细胞的增殖抑制剂 |
AU2015262349A AU2015262349A1 (en) | 2014-05-21 | 2015-05-20 | Cancer stem cell proliferation inhibitor |
ES15796913T ES2928499T3 (es) | 2014-05-21 | 2015-05-20 | Inhibición de la proliferación de células madre cancerosas |
EP15796913.0A EP3146978B1 (en) | 2014-05-21 | 2015-05-20 | Inhibition of cancer stem cell proliferation |
MX2016015092A MX2016015092A (es) | 2014-05-21 | 2015-05-20 | Inhibidor de proliferacion de celulas madre cancerosas. |
JP2016521132A JPWO2015178426A1 (ja) | 2014-05-21 | 2015-05-20 | がん幹細胞の増殖抑制剤 |
CN202210166733.7A CN114392252A (zh) | 2014-05-21 | 2015-05-20 | 癌干细胞的增殖抑制剂 |
US16/672,783 US20200061007A1 (en) | 2014-05-21 | 2019-11-04 | Cancer stem cell proliferation inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-105543 | 2014-05-21 | ||
JP2014105543 | 2014-05-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/312,484 A-371-Of-International US20170079942A1 (en) | 2014-05-21 | 2015-05-20 | Cancer stem cell proliferation inhibitor |
US16/672,783 Division US20200061007A1 (en) | 2014-05-21 | 2019-11-04 | Cancer stem cell proliferation inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015178426A1 true WO2015178426A1 (ja) | 2015-11-26 |
Family
ID=54554092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/064523 WO2015178426A1 (ja) | 2014-05-21 | 2015-05-20 | がん幹細胞の増殖抑制剤 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170079942A1 (ja) |
EP (1) | EP3146978B1 (ja) |
JP (1) | JPWO2015178426A1 (ja) |
KR (1) | KR20170005069A (ja) |
CN (2) | CN114392252A (ja) |
AU (1) | AU2015262349A1 (ja) |
CA (1) | CA2949640A1 (ja) |
ES (1) | ES2928499T3 (ja) |
MX (1) | MX2016015092A (ja) |
RU (1) | RU2016150116A (ja) |
TW (1) | TW201607531A (ja) |
WO (1) | WO2015178426A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
WO2021261601A1 (ja) * | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
WO2022150625A1 (en) * | 2021-01-08 | 2022-07-14 | Syros Pharmaceuticals, Inc. | Treatment regimens with fixed doses of tamibarotene |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2969031A4 (en) | 2013-03-15 | 2017-03-08 | Avisenna Cosmetics LLC | Topical compositions for reducing aging effects |
IT201800005072A1 (it) * | 2018-05-04 | 2019-11-04 | Nuovi farmaci prosenescenza | |
CN114045259B (zh) * | 2021-11-08 | 2024-04-05 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007108272A1 (ja) * | 2006-03-23 | 2007-09-27 | Tmrc Co., Ltd. | 癌治療用キットおよび癌治療用医薬組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090227674A1 (en) * | 2005-08-18 | 2009-09-10 | Richon Victoria M | Combination methods fo saha and targretin for treating cancer |
-
2015
- 2015-05-20 MX MX2016015092A patent/MX2016015092A/es unknown
- 2015-05-20 CA CA2949640A patent/CA2949640A1/en not_active Abandoned
- 2015-05-20 AU AU2015262349A patent/AU2015262349A1/en not_active Abandoned
- 2015-05-20 US US15/312,484 patent/US20170079942A1/en not_active Abandoned
- 2015-05-20 EP EP15796913.0A patent/EP3146978B1/en active Active
- 2015-05-20 CN CN202210166733.7A patent/CN114392252A/zh active Pending
- 2015-05-20 KR KR1020167034364A patent/KR20170005069A/ko unknown
- 2015-05-20 WO PCT/JP2015/064523 patent/WO2015178426A1/ja active Application Filing
- 2015-05-20 CN CN201580025982.2A patent/CN106456770A/zh active Pending
- 2015-05-20 RU RU2016150116A patent/RU2016150116A/ru not_active Application Discontinuation
- 2015-05-20 JP JP2016521132A patent/JPWO2015178426A1/ja active Pending
- 2015-05-20 ES ES15796913T patent/ES2928499T3/es active Active
- 2015-05-21 TW TW104116251A patent/TW201607531A/zh unknown
-
2019
- 2019-11-04 US US16/672,783 patent/US20200061007A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007108272A1 (ja) * | 2006-03-23 | 2007-09-27 | Tmrc Co., Ltd. | 癌治療用キットおよび癌治療用医薬組成物 |
Non-Patent Citations (8)
Title |
---|
GINESTIER, C. ET AL.: "Retinoid signaling regulates breast cancer stem cell differentiation", CELL CYCLE, vol. 8, no. 20, 2009, pages 3297 - 302, XP055001900 * |
LIM, Y. C. ET AL.: "All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/beta-catenin pathway", EUR. J. CANCER., vol. 48, no. 17, 2012, pages 3310 - 8, XP055164476 * |
NALLS, D. ET AL.: "Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells", PLOS ONE, 2011, pages e24099, XP055360806, Retrieved from the Internet <URL:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024099> [retrieved on 20150622] * |
OHTA, K. ET AL.: "Potent retinoid synergists with a diphenylamine skeleton", BIOL PHARM BULL, vol. 21, no. 5, 1998, pages 544 - 6, XP055238568 * |
OKAMURA, T. ET AL.: "Activation of Retinoic Acid Receptor a is Important for the Anti-myeloma Effect of Retinoids: New Therapeutic Approach Using Receptor Selective Retinoids for Multiple Myeloma", JOURNAL OF TOKYO WOMENS MEDICAL UNIVERSITY, vol. 83, 2013, pages E576 - E584, XP008185812 * |
See also references of EP3146978A4 * |
SHUICHI OKADA: "Atarashii Koganzai no Tenkai", SHOKAKIBYO SEMINAR, vol. 80, 2000, pages 167 - 75, XP008185811 * |
WHITWORTH, J. M. ET AL.: "The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells", GYNECOL. ONCOL., vol. 125, no. 1, 2012, pages 226 - 230, XP055238566 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
WO2021261601A1 (ja) * | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
JPWO2021261601A1 (ja) * | 2020-06-26 | 2021-12-30 | ||
JP7327855B2 (ja) | 2020-06-26 | 2023-08-16 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
WO2022150625A1 (en) * | 2021-01-08 | 2022-07-14 | Syros Pharmaceuticals, Inc. | Treatment regimens with fixed doses of tamibarotene |
Also Published As
Publication number | Publication date |
---|---|
TW201607531A (zh) | 2016-03-01 |
US20200061007A1 (en) | 2020-02-27 |
US20170079942A1 (en) | 2017-03-23 |
EP3146978A1 (en) | 2017-03-29 |
KR20170005069A (ko) | 2017-01-11 |
EP3146978A4 (en) | 2017-12-20 |
RU2016150116A3 (ja) | 2018-09-25 |
JPWO2015178426A1 (ja) | 2017-04-20 |
CN106456770A (zh) | 2017-02-22 |
CA2949640A1 (en) | 2015-11-26 |
MX2016015092A (es) | 2017-05-09 |
RU2016150116A (ru) | 2018-06-22 |
ES2928499T3 (es) | 2022-11-18 |
AU2015262349A1 (en) | 2017-02-02 |
CN114392252A (zh) | 2022-04-26 |
EP3146978B1 (en) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015178426A1 (ja) | がん幹細胞の増殖抑制剤 | |
Hu et al. | Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT | |
KR102490334B1 (ko) | 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증 | |
Baharuddin et al. | Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines | |
Mirzaei et al. | The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators | |
Tang et al. | Therapeutic applications of histone deacetylase inhibitors in sarcoma | |
Yee et al. | Transient receptor potential channel TRPM8 is over-expressed and required for cellular proliferation in pancreatic adenocarcinoma | |
ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
Wang et al. | Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil | |
Hui et al. | The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo | |
Han et al. | Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB | |
Joung et al. | Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway | |
Huang et al. | Studies on the anti‑angiogenic effect of Marsdenia tenacissima extract in vitro and in vivo | |
US9801844B2 (en) | Methods and compositions for the treatment of cancer | |
Wang et al. | Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway | |
Li et al. | Inhibition of Stat3 signaling pathway by natural product pectolinarigenin attenuates breast cancer metastasis | |
JP2018508196A (ja) | 抗老化化合物及びその使用 | |
Zhao et al. | Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo | |
Song et al. | Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells | |
Wang et al. | The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation | |
JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
Zhang et al. | Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression | |
US10597398B2 (en) | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | |
Jiang et al. | Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process | |
Huang et al. | Evidence that high-migration drug-surviving MOLT4 leukemia cells exhibit cancer stem cell-like properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15796913 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016521132 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/015092 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2949640 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15312484 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20167034364 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015796913 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015796913 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016150116 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015262349 Country of ref document: AU Date of ref document: 20150520 Kind code of ref document: A |